# Heart Failure Gets a New Definition, Experts Say It Will Transform Care
Cardiologists have updated how they define and classify heart failure, a shift that experts say will reshape patient care and treatment decisions.
The new definition broadens the understanding of heart failure beyond traditional measures of how forcefully the heart pumps blood. Instead, it now emphasizes structural or functional abnormalities that impair the heart's ability to fill or eject blood, even when ejection fraction measurements fall within normal ranges.
This change matters because many patients with heart failure symptoms have been overlooked under older diagnostic frameworks. The previous classification system relied heavily on ejection fraction measurements. That approach missed people whose hearts stiffened or failed to relax properly, a condition called diastolic dysfunction. Women and older adults were particularly underdiagnosed under the old system.
The updated definition introduces clearer categories that help doctors identify patients earlier and tailor treatment more precisely. Rather than relying on a single measurement, clinicians now consider multiple factors including imaging results, biomarkers like BNP or NT-proBNP, and clinical symptoms.
Cardiologists expect this redefinition to accelerate the pace of diagnosis. Patients with preserved ejection fraction, a group that makes up roughly half of all heart failure cases, will now receive more consistent recognition and access to emerging therapies. Several newer medications show promise in this population, but patients must first be properly diagnosed.
The change also standardizes language across healthcare systems. When cardiologists, primary care doctors, and specialists use the same definition, communication improves and gaps in care narrow.
For patients, this means more people will get identified as having heart failure before their condition becomes critical. Earlier diagnosis creates opportunities for preventive interventions like lifestyle modifications and medications that slow disease progression.
The European Society of Cardiology and American College of Cardiology endorsed this approach, sign